NeuralStem
ProfileJobs

NeuralStem

Suggest Edit
    • Healthbiotechdrug developmenttherapy

    NeuralStem is a clinical-stage biopharmaceutical company. The Company's patented technology enables the commercial-scale production of multiple types of central nervous system stem cells, which are under development for the potential treatment of Ischemic Paraplegia, Traumatic Spinal Cord Injury, ALS and Parkinsona's Disease. NeuralStem's research has allowed them to produce mature, commercial quantities of neural stem cells that can be transplanted into humans as treatments for currently incurable diseases.


    Revenue(FY, 2016)
    $16.2 K
    Market capitalization(2018-04-23)
    $21.4 M
    Type
    Public
    HQ
    Rockville, US
    Founded
    1996
    Size (employees)
    11 (est)
    Website
    neuralstem.com
    NeuralStem was founded in 1996 and is headquartered in Rockville, US
    Report incorrect company information

    NeuralStem Office Locations

    NeuralStem has an office in Rockville
    Rockville, US (HQ)
    9700 Great Seneca Highway
    Show all (1)
    Report incorrect company information

    NeuralStem Financials and Metrics

    NeuralStem Financials

    NeuralStem's revenue was reported to be $16.25 k in FY, 2016
    USD

    Revenue (FY, 2016)

    		16.2 k

    Net income (FY, 2016)

    		(21.1 m)

    EBIT (FY, 2016)

    		(20.6 m)

    Market capitalization (23-Apr-2018)

    		21.4 m

    Cash (31-Dec-2016)

    		15.2 m
    NeuralStem's current market capitalization is $21.4 m.
    Annual
    USDFY, 2016

    Revenue

    		16.2 k

    General and administrative expense

    		7.5 m

    Operating expense total

    		7.5 m

    EBIT

    		(20.6 m)
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

    Revenue

    		5 k5 k2.9 k2.5 k2.5 k2.5 k

    General and administrative expense

    		1.5 m2 m1.4 m1.7 m1.8 m3.2 m

    R&D expense

    		1.9 m2.1 m3.2 m3.3 m3.4 m3.1 m

    Operating expense total

    		3.4 m4 m4.6 m5 m5.2 m6.2 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Cash

    		16.8 m12.5 m4.7 m15.2 m

    Current Assets

    		17.6 m28.2 m13.5 m20.9 m
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

    Cash

    		15.2 m11.9 m13.6 m8.6 m13.1 m7.6 m

    Current Assets

    		30.8 m27.7 m29.2 m24.7 m19.6 m8.7 m

    PP&E

    		310.1 k301.3 k282.1 k343 k335.9 k337 k

    Total Assets

    		32.6 m29.4 m30.8 m26.4 m21.1 m10.2 m
    show all
    Annual
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    		(19.8 m)(22.6 m)(20.9 m)(21.1 m)

    Depreciation and Amortization

    		244.7 k348.6 k345.5 k337.5 k

    Accounts Payable

    		(116.8 k)1.4 m(1 m)879.1 k
    Quarterly
    USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016

    Net Income

    		(6.8 m)(4.5 m)(5.1 m)(5.4 m)(5.6 m)(6.6 m)

    Depreciation and Amortization

    		86.7 k83 k

    Accounts Payable

    		2 m2.4 m2.1 m2.1 m2 m2.6 m
    show all
    USDY, 2016

    Financial Leverage

    		2 x
    Show all financial metrics
    Report incorrect company information

    Competitors

    InVivo Therapeutics
    Health - Public
    Albireo Pharma
    Health - Public
    Innocare
    Health - Private
    Nordic Nanovector
    Health - Public
    Compare competitors
    Download PDF